Dr. Caroline MacCallum
Head of Medicine
FRCPC (Internal medicine), BSc Pharm
Clinical Instructor, Faculty of Medicine, UBC
Internist, VGH Dept Hematology/BMT & UBC Hospital
Medical Director, Greenleaf Medical Clinic
Special Interest in Complex Pain and Cannabinoid Medicine
Dr. MacCallum completed her undergraduate degree in pharmacy and medicine at the Memorial University of Newfoundland, where she was born and raised. She graduated from the University of British Columbia Internal Medicine Residency Program in 2013.
Upon graduation, Dr. MacCallum practiced Pain & Addiction Medicine at Vancouver General Hospital and the Heartwood Addiction Program at BC Women’s Hospital. In addition, she also practiced complex pain medicine at the CHANGEpain Clinic and BC Women’s Complex Chronic Disease Program.
Currently, she is a clinical instructor in the Department of Medicine at UBC where she provides inpatient care on the Internal Medicine Ward at UBC Hospital and Bone Marrow Transplant Ward at VGH. She is also a guest lecturer and preceptor for the UBC Faculty of Pharmaceutical Sciences Program.
She is also the Medical Director at Greenleaf Medical Clinic; a cannabis clinic in Langley, British Columbia which assesses patients’ suitability for therapy with legal, Health Canada approved medical cannabis. Greenleaf also offers group medical visits to provide patients with additional tools to manage their complex pain including; pain neurosciences, therapeutic movement, meditation, sleep, nutrition, and medicinal cannabis groups.
Dr. MacCallum has a passion for cannabis education and has done a number of CME presentations and preceptorships for physicians, pharmacists, nurses, and other allied health care professionals. Her research interest includes cannabis as a multimodal therapeutic for the treatment of concurrent medical conditions and symptom clusters (pain, mood, anxiety, insomnia); safe use of medical cannabis to improved function and quality of life; cannabis to help taper prescription medications (opioids, benzodiazepines etc.) to reduce overall polypharmacy burden; cannabis product safety (standardization, testing, and contaminants), cannabis and public health and safety including cannabis impairment and cannabis use in the workplace.